Sysmex (OTCMKTS:SSMXY) Shares Down 9.2% - Time to Sell?

Key Points

• Sysmex Corporation shares fell by 9.2%, trading as low as $13.84, significantly below its previous closing price of $15.26.
• The company reported quarterly earnings of $0.12 per share, missing consensus estimates of $0.16, alongside a revenue of $958.89 million versus an expectation of $991.22 million.
• With a market capitalization of $8.66 billion, Sysmex has a debt-to-equity ratio of 0.12 and a current ratio of 2.97, indicating a strong liquidity position.

Sysmex Corporation ADR (OTCMKTS:SSMXY - Get Free Report) was down 9.2% during mid-day trading on Thursday . The stock traded as low as $13.84 and last traded at $13.86. Approximately 20,050 shares were traded during trading, a decline of 76% from the average daily volume of 82,834 shares. The stock had previously closed at $15.26.

Sysmex Trading Down 9.8%

The business has a fifty day moving average price of $16.79 and a 200 day moving average price of $17.84. The company has a market capitalization of $8.66 billion, a price-to-earnings ratio of 24.57 and a beta of 1.15. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.97 and a quick ratio of 2.30.

Sysmex (OTCMKTS:SSMXY - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.16 by ($0.04). Sysmex had a return on equity of 11.81% and a net margin of 10.56%. The firm had revenue of $958.89 million for the quarter, compared to the consensus estimate of $991.22 million. On average, equities analysts expect that Sysmex Corporation ADR will post 0.57 EPS for the current fiscal year.

About Sysmex

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. The company also provides automated urine particle analyzers; automated blood coagulation analyzers; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.